HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revlon’s Stahl speaks out

This article was originally published in The Rose Sheet

Executive Summary

Improving business execution and developing consumer- and retail partner-based growth strategies are among top priorities for the company for "foreseeable future," CEO Jack Stahl says May 9, offering analysts insight into his plans to improve the faltering business. Increased "marketing pressure" is being inplemented now as one element. "I think we're going to have a lot to tap into as Revlon re-establishes its core brand positioning and really begins to reclaim its heritage as a power brand," Stahl states. Company will further unveil strategies for growth during an analyst conference tentatively scheduled for Aug. 2, exec adds. Stahl succeeded Jeffrey Nugent as president in February (1"The Rose Sheet" Feb. 25, 2002, p. 6)...

You may also be interested in...

Revlon Brand Management Responsibilities To Be Assigned By New CEO Stahl

One of the first tasks facing Revlon's newly-appointed President and CEO Jack Stahl will be delegating management duties for the company's key Revlon brand following the resignation of Revlon Brand Equity Group Exec VP and General Manger Cheryl Vitali

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts